Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials

Table 1 Summary of patient demographics for the OCEAN population, by indication

Primary indication	N	Age mean ± SD (years)	Gender, n (%)		BMI mean ± SD (kg/m²)	Time since diagnosis of primary indication mean ± SD (years)^a	Baseline VA
Primary indication	N	Age mean ± SD (years)	male	female	BMI mean ± SD (kg/m²)		ETDRS letters analogue (mean ± SD)
Overall^b	5606	74.6 ± 10.3	2451 (43.72)	3136 (55.94)	27.3 ± 4.5	0.56 ± 1.38	53.9 ± 20.6
nAMD^c	3614	77.9 ± 8.2	1393 (38.5)	2210 (61.2)	26.6 ± 4.0	0.53 ± 1.28	52.0 ± 21.3
DME^d	1211	67.6 ± 10.9	698 (57.6)	507 (41.9)	29.3 ± 5.2	0.68 ± 1.63	60.6 ± 15.5
RVO^e	741	71.0 ± 11.0	350 (47.23)	389 (52.50)	27.1 ± 4.3	0.49 ± 1.30	52.0 ± 22.7
BRVO^f	204	71.2 ± 10.0	85 (41.7)	119 (58.3)	27.1 ± 4.3	0.53 ± 1.37	55.9 ± 20.9
CRVO^g	121	70.3 ± 11.5	57 (47.1)	64 (52.9)	26.8 ± 4.4	0.32 ± 0.54	43.7 ± 25.0

Further details for the OCEAN populations are provided in Additional file 1: Table S1, Additional file 3: Table S3, Additional file 4: Table S4, Additional file 5: Table S5, Additional file 6: Table S6, Additional file 7: Table S7
^a Time since diagnosis of primary indication until first injection in OCEAN study
^b Overall: Missing values: age: 25 patients; gender: 19; BMI: 413; time since diagnosis: 281; baseline VA: 47
^c nAMD: Missing values: age: 14 patients; gender: 11; BMI: 230; time since diagnosis: 199; baseline VA: 29
^d DME: Missing values: age: 9 patients; gender: 6; BMI: 87; time since diagnosis: 65; baseline VA: 8
^e RVO: Missing values: type of RVO (B/C): 416 patients; age: 2; gender: 2; BMI: 56; time since diagnosis: 17; baseline VA: 10
^f BRVO: Missing values: age and gender: 0 patients; BMI: 8; time since diagnosis: 3; baseline VA: 1
^g CRVO: Missing values: age and gender: 0 patients; BMI: 2; time since diagnosis: 3; baseline VA: 3
Abbreviations: BMI: body mass index; BRVO: branch retinal vein occlusion; CRVO: central retinal vein occlusion; DME: diabetic macular oedema; ETDRS: Early Treatment Diabetic Retinopathy Study; N: total number of patients; n: number of patients; nAMD: neovascular age-related macular degeneration; RVO: retinal vein occlusion; SD: standard deviation; VA: visual acuity

ISSN: 1471-2415